Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

163 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Outcome for patients with relapsed/refractory aggressive lymphoma treated with gemcitabine and oxaliplatin with or without rituximab; a retrospective, multicentre study.
Dhanapal V, Gunasekara M, Lianwea C, Marcus R, De Lord C, Bowcock S, Devereux S, Patten P, Yallop D, Wrench D, Fields P, Kassam S. Dhanapal V, et al. Among authors: devereux s. Leuk Lymphoma. 2017 Sep;58(9):1-9. doi: 10.1080/10428194.2016.1276288. Epub 2017 Jan 16. Leuk Lymphoma. 2017. PMID: 28093003
Tumor-derived IL-6 may contribute to the immunological defect in CLL.
Buggins AG, Patten PE, Richards J, Thomas NS, Mufti GJ, Devereux S. Buggins AG, et al. Among authors: devereux s. Leukemia. 2008 May;22(5):1084-7. doi: 10.1038/sj.leu.2405015. Epub 2007 Nov 1. Leukemia. 2008. PMID: 17972945 No abstract available.
Lymphoma diagnosis: an update.
Patten PE, Devereux S. Patten PE, et al. Among authors: devereux s. Clin Med (Lond). 2007 Dec;7(6):620-4. doi: 10.7861/clinmedicine.7-6-620. Clin Med (Lond). 2007. PMID: 18193715 Free PMC article. Review. No abstract available.
The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial.
Burnett AK, Milligan D, Goldstone A, Prentice A, McMullin MF, Dennis M, Sellwood E, Pallis M, Russell N, Hills RK, Wheatley K; United Kingdom National Cancer Research Institute Haematological Oncology Study Group. Burnett AK, et al. Br J Haematol. 2009 May;145(3):318-32. doi: 10.1111/j.1365-2141.2009.07604.x. Epub 2009 Mar 8. Br J Haematol. 2009. PMID: 19291085 Free article. Clinical Trial.
Interaction with vascular endothelium enhances survival in primary chronic lymphocytic leukemia cells via NF-kappaB activation and de novo gene transcription.
Buggins AG, Pepper C, Patten PE, Hewamana S, Gohil S, Moorhead J, Folarin N, Yallop D, Thomas NS, Mufti GJ, Fegan C, Devereux S. Buggins AG, et al. Among authors: devereux s. Cancer Res. 2010 Oct 1;70(19):7523-33. doi: 10.1158/0008-5472.CAN-10-1634. Epub 2010 Aug 24. Cancer Res. 2010. PMID: 20736369
CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL.
Majid A, Lin TT, Best G, Fishlock K, Hewamana S, Pratt G, Yallop D, Buggins AG, Wagner S, Kennedy BJ, Miall F, Hills R, Devereux S, Oscier DG, Dyer MJ, Fegan C, Pepper C. Majid A, et al. Among authors: devereux s. Leuk Res. 2011 Jun;35(6):750-6. doi: 10.1016/j.leukres.2010.10.022. Epub 2010 Nov 18. Leuk Res. 2011. PMID: 21093051
163 results